Expand BBIO Menu
BBIO MENU

BBIO Latest Press Releases

-- December 13, 2024 --

Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Globe Newswire 7:18 AM

-- December 3, 2024 --

Unnatural Products Announces BridgeBio Exercises Option to License Macrocyclic Therapeutics for Development in Rare Diseases and Oncology Globe Newswire 8:00 AM

-- November 22, 2024 --

Attruby (acoramidis), a Near Complete TTR Stabilizer (=90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients Globe Newswire 7:11 PM

-- November 18, 2024 --

Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months Globe Newswire 11:15 AM
BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia Globe Newswire 5:30 AM

-- November 12, 2024 --

BridgeBio Pharma Reports Third Quarter 2024 Financial Results and Business Update Globe Newswire 7:30 AM

-- November 5, 2024 --

BridgeBio Announces Publication of Case Study Exploring Portfolio Theory's Impact on Biomedical Innovation in The Journal of Portfolio Management Globe Newswire 7:30 AM

-- October 24, 2024 --

BridgeBio Shares Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study of Gene Therapy BBP-812 for Canavan Disease at ESGCT 2024 Globe Newswire 7:30 AM

-- October 3, 2024 --

BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions Globe Newswire 7:30 AM

-- September 30, 2024 --

BridgeBio Completes Enrollment of FORTIFY, Phase 3 Registrational Study of BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9) Globe Newswire 7:30 AM

-- September 27, 2024 --

BridgeBio Shares Recurrent Event Analysis of ATTRibute-CM, Demonstrating a 42% Reduction by Acoramidis on the Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular-related Hospitalization Events Globe Newswire 6:00 PM

-- September 17, 2024 --

BridgeBio Announces Infigratinib Is the First Ever Investigational Therapeutic Option for Achondroplasia to Be Awarded Breakthrough Therapy Designation by the FDA Globe Newswire 7:30 AM

-- September 10, 2024 --

BridgeBio Pharma Reports Topline Results from Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH) Globe Newswire 4:45 PM
BridgeBio Receives FDA's Regenerative Medicine Advanced Therapy (RMAT) Designation for BBP-812 Canavan Disease Gene Therapy Program Globe Newswire 4:45 PM

-- September 6, 2024 --

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 7:30 AM

-- August 30, 2024 --

BRIDGEBIO PHARMA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates BridgeBio Pharma, Inc. - BBIO Business Wire 5:18 PM
BridgeBio Shares Data on Serum TTR Increase When Switching Participants from Placebo and Tafamidis to Acoramidis in ATTRibute-CM and its Open-Label Extension Globe Newswire 10:50 AM

-- August 29, 2024 --

BridgeBio to Present Additional Analyses from the Phase 3 ATTRibute-CM Trial of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the ESC Congress 2024 and the HFSA Annual Meeting 2024 Globe Newswire 7:30 AM

-- August 28, 2024 --

BridgeBio Pharma to Participate in September Investor Events Globe Newswire 7:30 AM

-- August 26, 2024 --

BridgeBio Partners with Leading Cardiovascular Data Science Lab (CarDS Lab) to Improve Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Diagnosis in Diverse Patient Populations with Multimodal Artificial Intelligence Globe Newswire 7:30 AM

-- August 19, 2024 --

BridgeBio Launches MyAchonJourney, a New Resource for Families Navigating Achondroplasia Globe Newswire 7:30 AM

-- August 8, 2024 --

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 7:30 AM

-- August 1, 2024 --

BridgeBio Pharma Reports Second Quarter 2024 Financial Results and Business Update Globe Newswire 7:30 AM

-- July 26, 2024 --

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BridgeBio Pharma, Inc. - BBIO Globe Newswire 12:27 PM

-- July 24, 2024 --

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BridgeBio Pharma, Inc. - BBIO PRNewswire 8:57 PM

-- July 23, 2024 --

BridgeBio Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer Globe Newswire 7:30 AM

-- July 20, 2024 --

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BridgeBio Pharma, Inc. - BBIO Globe Newswire 10:49 AM

-- July 18, 2024 --

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BridgeBio Pharma, Inc. - BBIO PRNewswire 9:37 PM